Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageOur products and services span the evolving continuum of care, including inpatient, outpatient, and retail settings. We provide a range of points of care medication and supply dispensing systems, including automated systems. We also offer advanced automation solutions including robotics designed to automate work, streamline workflows, and reduce human error. Across these settings, we provide central pharmacy automation solutions for both medication dispensing and IV compounding.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $309.9MThe company’s own SEC segment disclosure.
- Connected Devices Software Licenses And Other$148.7M48%
- Saa S And Expert Services$68.2M22%
- Technical Services$66.9M22%
- Consumables$26.1M8%
Omnicell, Inc. (OMCL) reported revenue of $310M in Q1 2026 (quarter ended March 31, 2026), up 15% from the same quarter a year earlier. That came with a gross margin of 45% and net income of $11M (3.7% of revenue). For the full year FY2025, revenue was $1.18B (+6.5% year on year) and net income $2.1M. Its largest product in 2026-Q1 was Connected Devices Software Licenses And Other at $149M, 48% of the disclosed total, just ahead of Saa S And Expert Services at 22%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Health Information Services
Ranks #11 of 14 by Smart Score